Course Title: Pharmacology CME Review Package
Price: $399.99 – $1,999.00
Credits: 12.0 AAPA Category 1 CME Credits
Access: 30 Months
Format: Online Video Review and Practice Questions
Add-ons: $100 – $1,500 Amazon or Apple Gift Cards Available
Pharmacology remains one of the most challenging domains for clinical practitioners. Whether you are preparing for the PANCE, the PANRE, or simply maintaining your clinical competency, the sheer volume of medications, mechanisms, and side effects can lead to rapid cognitive fatigue. For many Physician Assistants and Nurse Practitioners, a standard review often fails to translate into long-term retention.
Our Pharmacology CME Review Package is designed to address these retention gaps while providing 12.0 AAPA Category 1 CME credits. If you find that your pharmacology knowledge is not "sticking," it is likely due to one of the following ten reasons.
1. Prioritizing Rote Memorization Over Mechanism
Memorizing drug names without understanding their mechanism of action (MOA) is a high-effort, low-reward strategy. When you understand how a drug interacts with a receptor or enzyme, the indications and adverse effects become logical conclusions rather than isolated facts. For instance, knowing that ACE inhibitors prevent the breakdown of bradykinin immediately explains the side effect of a dry cough.
2. Ignoring Suffixes and Class Prefixes
Many clinicians fail to utilize the systematic nomenclature of pharmacology. Grouping drugs by suffixes (e.g., -olol for beta-blockers, -flozin for SGLT2 inhibitors) allows you to learn the characteristics of an entire class once, rather than re-learning them for every individual agent.
3. Lack of Spaced Repetition
The "forgetting curve" is steep in pharmacology. Reviewing a topic once and moving on ensures that much of the information will be lost within 48 hours. Using spaced repetition: reviewing the material at increasing intervals: is essential for moving information from short-term to long-term memory.
4. Delayed Application of Practice Questions
Waiting until you "know the material" to start practice questions is a common mistake. Questions should be used as a primary learning tool, not just a final assessment. Early exposure to clinical vignettes helps identify exactly how the NCCPA or other boards will test the material.
5. Failure to Group by Clinical Indication
Studying drugs in alphabetical order or by manufacturer is inefficient. You must study pharmacology in the context of the organ systems they treat. Our courses are structured by system: Cardiology, Pulmonology, Neurology, and more: to mirror how you actually treat patients in the clinic.
6. Skipping Pharmacokinetic Fundamentals
If you do not understand half-life, volume of distribution, or the cytochrome P450 system, you will struggle with dosing and drug-drug interactions. These fundamentals provide the framework upon which all clinical pharmacology is built.
7. Passive vs. Active Review
Reading a textbook or watching a video without active engagement is passive. You must interact with the material. Our CME packages include interactive components and gift card add-ons to Amazon and Apple, allowing you to purchase additional tools like medical tablets or physical texts to enhance your active study sessions.
8. Over-reliance on Complex Mnemonics
While some mnemonics are helpful, creating a complex story for every drug adds an extra layer of information you have to memorize. If the mnemonic is harder to remember than the drug's side effect, it is counterproductive. Stick to simple, high-yield associations.
9. Not Linking Pharmacology to Clinical Scenarios
Abstract pharmacology is difficult to retain. You must visualize the patient. Seeing a drug's effect in the context of a "real-world" scenario, such as an elderly patient with multiple comorbidities, makes the information far more "sticky."
10. Using Outdated Resources
Guidelines for pharmacology change rapidly, particularly in areas like cardiology (anticoagulation) and endocrinology (diabetes management). Using materials from three years ago can lead to incorrect answers on exams and, more importantly, incorrect treatment in practice.
Clinical Assessment
The following scenarios are designed to test your application of clinical pharmacology.
Question 1
Patient: 64-year-old male
Symptoms: Progressive shortness of breath and peripheral edema
Vitals: HR 88, BP 142/88, SaO2 94% on RA
Scenario: Your patient has a history of Heart Failure with Reduced Ejection Fraction (HFrEF). You are considering adding a medication that has been shown to reduce mortality and hospitalizations by inhibiting neprilysin.
Which of the following is a mandatory requirement before initiating this therapy?
A. A 36-hour washout period after the last dose of an ACE inhibitor
B. Baseline serum potassium below 4.0 mEq/L
C. Discontinuation of all beta-blocker therapy
D. Documentation of an ejection fraction above 40%
Answer: A. A 36-hour washout period after the last dose of an ACE inhibitor.
Sacubitril/valsartan (Entresto) combines a neprilysin inhibitor with an ARB. Because both ACE inhibitors and neprilysin inhibitors increase bradykinin levels, simultaneous use or insufficient washout periods significantly increase the risk of life-threatening angioedema. A 36-hour window is required when transitioning from an ACE inhibitor to an ARNI.
Question 2
Patient: 28-year-old female
Symptoms: Sudden onset of wheezing and chest tightness
Vitals: HR 110, BP 120/78, RR 24, SaO2 92% on RA
Scenario: The patient is diagnosed with an acute asthma exacerbation. After administration of a short-acting beta-agonist (SABA), you decide to add an inhaled muscarinic antagonist.
What is the primary mechanism of action for the added medication?
A. Stabilization of mast cell membranes
B. Competitive inhibition of acetylcholine at muscarinic receptors
C. Non-selective blockade of beta-2 receptors
D. Inhibition of leukotriene synthesis
Answer: B. Competitive inhibition of acetylcholine at muscarinic receptors.
Ipratropium bromide is a Short-Acting Muscarinic Antagonist (SAMA). It works by blocking the bronchoconstrictor effects of acetylcholine on the smooth muscle of the airways, providing an additive bronchodilatory effect when used with SABAs in acute settings.
Question 3
Patient: 52-year-old male
Symptoms: Acute, severe pain and swelling in the first metatarsophalangeal joint
Vitals: HR 92, BP 138/86, Temp 99.1°F
Scenario: You diagnose the patient with an acute gouty flare. He has a history of stage 3 Chronic Kidney Disease (CKD).
Which of the following medications is most appropriate for acute management given his renal status?
A. High-dose Aspirin
B. Naproxen
C. Colchicine with dosage adjustment
D. Prednisone
Answer: D. Prednisone.
In patients with significant CKD, NSAIDs (like naproxen) should be avoided due to the risk of acute kidney injury and fluid retention. While colchicine can be used, it requires significant dosage reduction and carries a higher risk of toxicity in renal impairment. Corticosteroids are often the safest and most effective choice for acute gout in the setting of moderate to severe renal disease.
Question 4
Patient: 72-year-old female
Symptoms: Tremor at rest and bradykinesia
Vitals: HR 72, BP 130/80
Scenario: The patient is being treated for Parkinson’s disease with levodopa/carbidopa. She reports that the effects of the medication are wearing off before her next dose is due. You decide to add an entacapone.
What is the purpose of adding entacapone to her regimen?
A. To block central dopamine receptors
B. To inhibit COMT and decrease peripheral metabolism of levodopa
C. To increase the renal excretion of carbidopa
D. To cross the blood-brain barrier and convert directly to dopamine
Answer: B. To inhibit COMT and decrease peripheral metabolism of levodopa.
Entacapone is a COMT inhibitor. By inhibiting the peripheral breakdown of levodopa, more levodopa remains available to cross the blood-brain barrier, thereby extending the duration of action and reducing "off" time in patients with Parkinson's disease.
Question 5
Patient: 45-year-old male
Symptoms: Routine physical, no complaints
Vitals: HR 76, BP 148/94
Scenario: The patient has a new diagnosis of Stage 2 Hypertension. His medical history is significant for Type 2 Diabetes Mellitus with albuminuria.
Which medication class is the most appropriate first-line therapy for this patient?
A. Calcium Channel Blockers
B. Thiazide Diuretics
C. ACE Inhibitors
D. Beta-Blockers
Answer: C. ACE Inhibitors.
For patients with diabetes and evidence of albuminuria (or CKD), ACE inhibitors or ARBs are the first-line antihypertensive agents. Beyond blood pressure control, these agents provide essential renoprotective effects by reducing intraglomerular pressure and slowing the progression of diabetic nephropathy.
Maximize your study time and your CME budget. Our Pharmacology Review Course offers the most efficient way to earn 12.0 AAPA Category 1 CME credits while refreshing your clinical knowledge. With the option to add an Amazon or Apple Gift Card (up to $1,500), you can invest in the technology and resources you need for your practice.
For those preparing for the recertification exam, our PANRE Review Course provides 100 hours of AAPA Category 1 CME credit, ensuring you are fully prepared for the NCCPA requirements.